Novel S-Gal® analogs as 1H MRI reporters for in vivo detection of β-galactosidase

Praveen K. Gulaka, Jian Xin Yu, Li Liu, Ralph P. Mason, Vikram D. Kodibagkar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The quantitative assessment of gene expression and related enzyme activity in vivo could be important for the characterization of gene altering diseases and therapy. The development of imaging techniques, based on specific reporter molecules may enable routine non-invasive assessment of enzyme activity and gene expression in vivo. We recently reported the use of commercially available S-Gal® as a β-galactosidase reporter for 1H MRI, and the synthesis of several S-Gal® analogs with enhanced response to β-galactosidase activity. We have now compared these analogs in vitro and have identified the optimal analog, C3-GD, based on strong T1 and T2 response to enzyme presence (δR1 and δR2~1.8 times S-Gal®). Moreover, application is demonstrated in vivo in human breast tumor xenografts. MRI studies in MCF7-lacZ tumors implanted subcutaneously in athymic nude mice (n=6), showed significant reduction in T1 and T2 values (each~13%) 2h after intra-tumoral injection of C3-GD, whereas the MCF7 (wild type) tumors showed slight increase. Thus, C3-GD successfully detects β-galactosidase activity in vivo and shows promise as a lacZ gene 1H MR reporter molecule.

Original languageEnglish (US)
Pages (from-to)1006-1011
Number of pages6
JournalMagnetic Resonance Imaging
Volume31
Issue number6
DOIs
StatePublished - Jul 2013

Fingerprint

Galactosidases
Magnetic resonance imaging
Tumors
Enzyme activity
Gene expression
Nude Mice
Enzymes
Genes
Gene Expression
Molecules
Lac Operon
Heterografts
Neoplasms
Breast Neoplasms
Imaging techniques
Injections
cyclohexenoesculetin-beta-galactoside
Therapeutics

Keywords

  • β-galactosidase
  • H MRI
  • Fe-chelation
  • Gene reporters
  • LacZ
  • Signal enhancement
  • T
  • T

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Biomedical Engineering

Cite this

Novel S-Gal® analogs as 1H MRI reporters for in vivo detection of β-galactosidase. / Gulaka, Praveen K.; Yu, Jian Xin; Liu, Li; Mason, Ralph P.; Kodibagkar, Vikram D.

In: Magnetic Resonance Imaging, Vol. 31, No. 6, 07.2013, p. 1006-1011.

Research output: Contribution to journalArticle

Gulaka, Praveen K. ; Yu, Jian Xin ; Liu, Li ; Mason, Ralph P. ; Kodibagkar, Vikram D. / Novel S-Gal® analogs as 1H MRI reporters for in vivo detection of β-galactosidase. In: Magnetic Resonance Imaging. 2013 ; Vol. 31, No. 6. pp. 1006-1011.
@article{f0de8e4b92a2410ca1ca1b974e46f588,
title = "Novel S-Gal{\circledR} analogs as 1H MRI reporters for in vivo detection of β-galactosidase",
abstract = "The quantitative assessment of gene expression and related enzyme activity in vivo could be important for the characterization of gene altering diseases and therapy. The development of imaging techniques, based on specific reporter molecules may enable routine non-invasive assessment of enzyme activity and gene expression in vivo. We recently reported the use of commercially available S-Gal{\circledR} as a β-galactosidase reporter for 1H MRI, and the synthesis of several S-Gal{\circledR} analogs with enhanced response to β-galactosidase activity. We have now compared these analogs in vitro and have identified the optimal analog, C3-GD, based on strong T1 and T2 response to enzyme presence (δR1 and δR2~1.8 times S-Gal{\circledR}). Moreover, application is demonstrated in vivo in human breast tumor xenografts. MRI studies in MCF7-lacZ tumors implanted subcutaneously in athymic nude mice (n=6), showed significant reduction in T1 and T2 values (each~13{\%}) 2h after intra-tumoral injection of C3-GD, whereas the MCF7 (wild type) tumors showed slight increase. Thus, C3-GD successfully detects β-galactosidase activity in vivo and shows promise as a lacZ gene 1H MR reporter molecule.",
keywords = "β-galactosidase, H MRI, Fe-chelation, Gene reporters, LacZ, Signal enhancement, T, T",
author = "Gulaka, {Praveen K.} and Yu, {Jian Xin} and Li Liu and Mason, {Ralph P.} and Kodibagkar, {Vikram D.}",
year = "2013",
month = "7",
doi = "10.1016/j.mri.2013.03.001",
language = "English (US)",
volume = "31",
pages = "1006--1011",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Novel S-Gal® analogs as 1H MRI reporters for in vivo detection of β-galactosidase

AU - Gulaka, Praveen K.

AU - Yu, Jian Xin

AU - Liu, Li

AU - Mason, Ralph P.

AU - Kodibagkar, Vikram D.

PY - 2013/7

Y1 - 2013/7

N2 - The quantitative assessment of gene expression and related enzyme activity in vivo could be important for the characterization of gene altering diseases and therapy. The development of imaging techniques, based on specific reporter molecules may enable routine non-invasive assessment of enzyme activity and gene expression in vivo. We recently reported the use of commercially available S-Gal® as a β-galactosidase reporter for 1H MRI, and the synthesis of several S-Gal® analogs with enhanced response to β-galactosidase activity. We have now compared these analogs in vitro and have identified the optimal analog, C3-GD, based on strong T1 and T2 response to enzyme presence (δR1 and δR2~1.8 times S-Gal®). Moreover, application is demonstrated in vivo in human breast tumor xenografts. MRI studies in MCF7-lacZ tumors implanted subcutaneously in athymic nude mice (n=6), showed significant reduction in T1 and T2 values (each~13%) 2h after intra-tumoral injection of C3-GD, whereas the MCF7 (wild type) tumors showed slight increase. Thus, C3-GD successfully detects β-galactosidase activity in vivo and shows promise as a lacZ gene 1H MR reporter molecule.

AB - The quantitative assessment of gene expression and related enzyme activity in vivo could be important for the characterization of gene altering diseases and therapy. The development of imaging techniques, based on specific reporter molecules may enable routine non-invasive assessment of enzyme activity and gene expression in vivo. We recently reported the use of commercially available S-Gal® as a β-galactosidase reporter for 1H MRI, and the synthesis of several S-Gal® analogs with enhanced response to β-galactosidase activity. We have now compared these analogs in vitro and have identified the optimal analog, C3-GD, based on strong T1 and T2 response to enzyme presence (δR1 and δR2~1.8 times S-Gal®). Moreover, application is demonstrated in vivo in human breast tumor xenografts. MRI studies in MCF7-lacZ tumors implanted subcutaneously in athymic nude mice (n=6), showed significant reduction in T1 and T2 values (each~13%) 2h after intra-tumoral injection of C3-GD, whereas the MCF7 (wild type) tumors showed slight increase. Thus, C3-GD successfully detects β-galactosidase activity in vivo and shows promise as a lacZ gene 1H MR reporter molecule.

KW - β-galactosidase

KW - H MRI

KW - Fe-chelation

KW - Gene reporters

KW - LacZ

KW - Signal enhancement

KW - T

KW - T

UR - http://www.scopus.com/inward/record.url?scp=84878658315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878658315&partnerID=8YFLogxK

U2 - 10.1016/j.mri.2013.03.001

DO - 10.1016/j.mri.2013.03.001

M3 - Article

VL - 31

SP - 1006

EP - 1011

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 6

ER -